New cocktail aims to snuff out residual AML before it returns
NCT ID NCT07148180
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs—tagraxofusp, azacitidine, and venetoclax—in adults with acute myeloid leukemia (AML) who are in remission but still have tiny amounts of cancer cells that standard tests miss. The goal is to see if the combo can safely clear these hidden cells and prevent relapse. The trial enrolls 31 participants across multiple sites.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tagraxofusp, azacitidine, and venetoclax
What this could lead to
If successful, this combination could help eliminate hidden leukemia cells and reduce the chance of the cancer coming back.
What could go wrong
This is an early-phase trial with only 31 participants, so safety and effectiveness are not yet proven. Side effects from the drug combination may occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact